Related Experiment Video
Updated: Mar 29, 2026
09:02
Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
Published on: February 15, 2018
20.1K
Is it safe to breastfeed while taking methylphenidate?
Canadian Family Physician Medecin De Famille Canadien
|December 2, 2015
Summary
Methylphenidate (MPH) is excreted in small amounts in breast milk with no reported adverse effects in infants. While MPH appears compatible with breastfeeding, long-term neurodevelopmental outcomes require further study.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Neurology
Background:
- Narcolepsy management during lactation presents challenges for breastfeeding mothers.
- Mothers may experience difficulties maintaining alertness, impacting infant care.
- Concerns exist regarding medication transfer to infants via breast milk.
Purpose of the Study:
- To evaluate the safety and compatibility of methylphenidate (MPH) use in breastfeeding mothers with narcolepsy.
- To determine if MPH use necessitates switching to formula feeding.
Main Methods:
- Literature review of studies on methylphenidate excretion in breast milk.
- Analysis of reported adverse effects in breastfed infants exposed to MPH.
- Assessment of current clinical recommendations regarding MPH and breastfeeding.
Main Results:
- Methylphenidate is present in breast milk in minimal quantities.
- No adverse effects have been documented in breastfed infants exposed to MPH.
- Available data suggest compatibility between MPH and breastfeeding.
Conclusions:
- Methylphenidate is generally considered safe for breastfeeding mothers with narcolepsy.
- Continued breastfeeding while taking MPH is a viable option.
- Further research is needed to ascertain long-term neurodevelopmental effects in exposed infants.
More Related Videos
Related Concept Videos
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
1.6K
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
1.6K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
373
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
01:24Antiasthma Drugs: Methylxanthines
2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
01:29Drug Dosing: Infants and Children
744
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
744
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
704
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
462
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462